靶向药物治疗宫颈癌的研究进展
摘要
一种新兴的治疗手段,为宫颈癌(CC)患者的治疗带来了新的希望。靶向治疗通过针对癌细胞特定分子或信号通
路来抑制肿瘤生长。本文综述了当前宫颈癌(CC)靶向治疗的研究进展,重点介绍了几种主要的靶向药物及其作
用机制。此外,本文还探讨了靶向治疗的临床试验结果,评估了其疗效与安全性。最后,分析了靶向治疗在宫颈癌
(CC)治疗中的未来发展方向与挑战,强调了个体化治疗的重要性。随着对宫颈癌(CC)生物学特性的深入理解,
靶向治疗有望成为提升患者预后的一项关键策略。
关键词
全文:
PDF参考
[1]Comprehensive Cervical Cancer Control: A
Guide to Essential Practice. 2nd ed. Geneva: World Health
Organization; 2014. PMID: 25642554.
[2]Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics
2020: GLOBOCAN Estimates of Incidence and Mortality
Worldwide for 36 Cancers in 185 Countries. CA Cancer J
Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.
Epub 2021 Feb 4. PMID: 33538338.
[3]Waggoner SE. Cervical cancer. Lancet. 2003
Jun 28;361(9376):2217-25. doi: 10.1016/S0140-
6736(03)13778-6. PMID: 12842378.
[4]Yavas G, Yavas C. Comment on‘Quality of life
and emotional distress in early stage and locally advanced
cervical cancer patients: a prospective, longitudinal study' by
Ferrandina et al. Gynecol Oncol 2012; 124: 389-94.
[5]Peralta-Zaragoza O, Bermúdez-Morales VH,
Madrid-Marina V. Targeted treatments for cervical cancer: a
review. Onco Targets Ther 2012; 5: 315-28.
[6]D'Abramo CM, Archambault J. Small molecule
inhibitors of human papillomavirus protein - protein
interactions. Open Virol J 2011; 5: 80-95
[7]Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase Ⅱ,
open-label study of pazopanib or lapatinib monotherapy
compared with pazopanib plus lapatinib combination therapy
in patients with advanced and recurrent cervical cancer. J Clin
Oncol 2010;28:3562-9. [PubMed]
[8]Tewari KS, Sill MW, Long HJ 3rd, et al. Improved
survival with bevacizumab in advanced cervical cancer. N
Engl J Med 2014;370:734-43.
[9]Khan MJ, Castle PE, Lorincz AT, Wacholder S,
Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.
The elevated 10-year risk of cervical precancer and cancer in
women with human papillomavirus (HPV) type 16 or 18 and
the possible utility of type-specific HPV testing in clinical
practice. J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9. doi:
10.1093/jnci/dji187. PMID: 16030305.
[10]Mesri EA, Feitelson MA, Munger K. Human
viral oncogenesis: a cancer hallmarks analysis. Cell Host
Microbe. 2014 Mar 12;15(3):266-82. doi: 10.1016/
j.chom.2014.02.011. PMID: 24629334; PMCID:
PMC3992243.
[11]Templeton CW, Laimins LA. p53-dependent
R-loop formation and HPV pathogenesis. Proc Natl Acad
Sci U S A. 2023 Aug 29;120(35):e2305907120. doi: 10.1073/
pnas.2305907120. Epub 2023 Aug 23. PMID: 37611058;
PMCID: PMC10467572.
[12]Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D,
Zoratto F, Benedetti Panici P, Tomao S. Angiogenesis and
antiangiogenic agents in cervical cancer. Onco Targets Ther.
2014 Dec 3;7:2237-48. doi: 10.2147/OTT.S68286. PMID:
25506227; PMCID: PMC4259513.
[13]Ferrara N. Vascular endothelial growth factor:
basic science and clinical progress. Endocr Rev. 2004
Aug;25(4):581-611. doi: 10.1210/er.2003-0027. PMID:
15294883.
[14]Yun HY, Kim MW, Lee HS, Kim W, Shin
JH, Kim H, Shin HC, Park H, Oh BH, Kim WK, Bae
KH, Lee SC, Lee EW, Ku B, Kim SJ. Structural basis for
recognition of the tumor suppressor protein PTPN14 by the
oncoprotein E7 of human papillomavirus. PLoS Biol. 2019
Jul 19;17(7):e3000367. doi: 10.1371/journal.pbio.3000367.
PMID: 31323018; PMCID: PMC6668832.
[15]马菁雯,张琰.宫颈癌组织中黏蛋白5B的表达
及与HPV E6/E7 mRNA表达关系[J].中国计划生育学杂
志,2024,32(09):2132-2135+2140+2217.
[16]Hatterschide J, Bohidar AE, Grace M, Nulton TJ,
Kim HW, Windle B, Morgan IM, Munger K, White EA.
PTPN14 degradation by high-risk human papillomavirus E7
limits keratinocyte differentiation and contributes to HPVmediated oncogenesis. Proc Natl Acad Sci U S A. 2019 Apr
2;116(14):7033-7042. doi: 10.1073/pnas.1819534116. Epub
2019 Mar 20. PMID: 30894485; PMCID: PMC6452706.
[17]Gonzalez SL, Stremlau M, He X, Basile JR,
Münger K. Degradation of the retinoblastoma tumor
suppressor by the human papillomavirus type 16 E7
oncoprotein is important for functional inactivation and
is separable from proteasomal degradation of E7. J Virol.
2001 Aug;75(16):7583-91. doi: 10.1128/JVI.75.16.7583-
7591.2001. PMID: 11462030; PMCID: PMC114993.
[18] Zhuang H, Shi S, Yuan Z, Chang JY. Bevacizumab
treatment for radiation brain necrosis: mechanism, efficacy
and issues. Mol Cancer. 2019 Feb 7;18(1):21. doi: 10.1186/
s12943-019-0950-1. PMID: 30732625; PMCID:
PMC6367784.
[19] Bevacizumab for advanced cervical cancer: final
overall survival and adverse event analysis of a randomised,
controlled, open-label, phase 3 trial (Gynecologic Oncology
Group 240)
[20]夏玲芳,朱俊,吴小华.2023年ESMO妇科肿瘤
治疗最新进展及展望[J].中国癌症杂志,2023,33(11):
969-980.DOI:10.19401/j.cnki.1007-3639.2023.11.001.
[21] Tewari KS, Sill MW, Long HJ 3rd, Penson RT,
Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid
TJ, Leitao MM, Michael HE, Monk BJ. Improved survival
with bevacizumab in advanced cervical cancer. N Engl J Med.
2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748.
Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. doi:
10.1056/NEJMx170002. PMID: 24552320; PMCID:
PMC4010094.
[22] Zarour HM. Reversing T-cell Dysfunction
and Exhaustion in Cancer. Clin Cancer Res. 2016 Apr
15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849.
PMID: 27084739; PMCID: PMC4872712.
[23] Li X, Shao C, Shi Y, Han W. Lessons learned
from the blockade of immune checkpoints in cancer
immunotherapy. J Hematol Oncol. 2018 Feb 27;11(1):31. doi:
10.1186/s13045-018-0578-4. PMID: 29482595; PMCID:
PMC6389077.
[24] Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S,
Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser
H, Heinemann V, Subklewe M, Boeck S, Werner J, von
Bergwelt-Baildon M. Advances in cancer immunotherapy
2019 - latest trends. J Exp Clin Cancer Res. 2019 Jun
19;38(1):268. doi: 10.1186/s13046-019-1266-0. PMID:
31217020; PMCID: PMC6585101.
[25] Jenkins RW, Barbie DA, Flaherty KT. Mechanisms
of resistance to immune checkpoint inhibitors. Br J Cancer.
2018 Jan;118(1):9-16. doi: 10.1038/bjc.2017.434. Epub 2018
Jan 2. PMID: 29319049; PMCID: PMC5765236.
[26]Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PDL1 in cancer immunotherapy: clinical implications and future
considerations. Hum Vaccin Immunother. 2019;15(5):1111-
1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar
19. PMID: 30888929; PMCID: PMC6605868.
[27] Lorusso D, Xiang Y, Hasegawa K, Scambia G,
Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N,
Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A,
Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli
J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL,
Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer
S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata
S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTEA18 investigators. Pembrolizumab or placebo with
chemoradiotherapy followed by pembrolizumab or placebo
for newly diagnosed, high-risk, locally advanced cervical
cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18):
a randomised, double-blind, phase 3 clinical trial. Lancet.
2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-
6736(24)00317-9. Epub 2024 Mar 20. PMID: 38521086.
[28] Monk BJ, Colombo N, Tewari KS, Dubot C,
Caceres MV, Hasegawa K, Shapira-Frommer R, Salman
P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M,
Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li
K, Keefe SM, Lorusso D; KEYNOTE-826 Investigators.
First-Line Pembrolizumab + Chemotherapy Versus
Placebo + Chemotherapy for Persistent, Recurrent, or
Metastatic Cervical Cancer: Final Overall Survival Results of
KEYNOTE-826. J Clin Oncol. 2023 Dec 20;41(36):5505-
5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1. PMID:
37910822.
[29] Oaknin A, Gladieff L, Martínez-García J,
Villacampa G, Takekuma M, De Giorgi U, Lindemann K,
Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz
A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L,
Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F,
Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo
JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM;
ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-
3030 Investigators. Atezolizumab plus bevacizumab and
chemotherapy for metastatic, persistent, or recurrent cervical
cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-
6736(23)02405-4. Epub 2023 Dec 1. PMID: 38048793.
[30] Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T,
Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B,
Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi
G, Johari B, Zali MR, Bagheri N. Antibody-drug conjugates
(ADCs) for cancer therapy: Strategies, challenges, and
successes. J Cell Physiol. 2019 May;234(5):5628-5642. doi:
10.1002/jcp.27419. Epub 2018 Nov 27. PMID: 30478951.
[31]黄佳,王浩,钟薇,等.治疗复发或转移性宫颈
癌的抗体偶联药物:Tisotumab Vedotin-tftv[J].肿瘤药学,
2022,12(04):428-432.
[32] Chen H, Lin Z, Arnst KE, Miller DD, Li W.
Tubulin Inhibitor-Based Antibody-Drug Conjugates for
Cancer Therapy. Molecules. 2017 Aug 1;22(8):1281. doi:
10.3390/molecules22081281. PMID: 28763044; PMCID:
PMC6152078.
[33] Coleman RL, Lorusso D, Gennigens C,
González-Martín A, Randall L, Cibula D, Lund B,
Woelber L, Pignata S, Forget F, Redondo A, Vindeløv
SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng
MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk
BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6
Collaborators. Efficacy and safety of tisotumab vedotin in
previously treated recurrent or metastatic cervical cancer
(innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre,
open-label, single-arm, phase 2 study. Lancet Oncol. 2021
May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5.
Epub 2021 Apr 9. PMID: 33845034.
[34] Vergote I, Van Nieuwenhuysen E, O'Cearbhaill
RE, Westermann A, Lorusso D, Ghamande S, Collins DC,
Banerjee S, Mathews CA, Gennigens C, Cibula D, Tewari
KS, Madsen K, Köse F, Jackson AL, Boere IA, Scambia G,
Randall LM, Sadozye A, Baurain JF, Gort E, Zikán M,
Denys HG, Ottevanger N, Forget F, Mondrup Andreassen C,
Eaton L, Chisamore MJ, Viana Nicacio L, Soumaoro I, Monk
BJ. Tisotumab Vedotin in Combination With Carboplatin,
Pembrolizumab, or Bevacizumab in Recurrent or Metastatic
Cervical Cancer: Results From the innovaTV 205/GOG-
3024/ENGOT-cx8 Study. J Clin Oncol. 2023 Dec
20;41(36):5536-5549. doi: 10.1200/JCO.23.00720. Epub
2023 Aug 31. PMID: 37651655; PMCID: PMC10730069.
[35] Vergote I, González-Martín A, Fujiwara K,
Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee
S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen
E, Manso L, Woelber L, Westermann A, Covens A,
Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz
FM, Angelergues A, Cibula D, Barraclough L, Oaknin A,
Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I,
Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057
Collaborators. Tisotumab Vedotin as Second- or Third-Line
Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024
Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. PMID:
38959480.
[36] Eshhar Z, Waks T, Gross G, Schindler DG.
Specific activation and targeting of cytotoxic lymphocytes
through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the
immunoglobulin and T-cell receptors. Proc Natl Acad Sci U
S A. 1993 Jan 15;90(2):720-4. doi: 10.1073/pnas.90.2.720.
PMID: 8421711; PMCID: PMC45737.
[37] Dwivedi A, Karulkar A, Ghosh S, Rafiq A,
Purwar R. Corrigendum: Lymphocytes in Cellular Therapy:
Functional Regulation of CAR T Cells. Front Immunol.
2019 Mar 8;10:401. doi: 10.3389/fimmu.2019.00401.
Erratum for: Front Immunol. 2019 Jan 18;9:3180. doi:
10.3389/fimmu.2018.03180. PMID: 30906295; PMCID:
PMC6418378.
[38] Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary
S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL,
Korrapati S, Stevanović S, Trimble CL, Kanakry JA, Bagheri
MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek
D, Gkitsas N, Highfill S, Hinrichs CS. TCR-engineered T
cells targeting E7 for patients with metastatic HPV-associated
epithelial cancers. Nat Med. 2021 Mar;27(3):419-425. doi:
10.1038/s41591-020-01225-1. Epub 2021 Feb 8. PMID:
33558725; PMCID: PMC9620481.
Refbacks
- 当前没有refback。